LiNing
Quick facts
Marketed products
- oxaliplatin plus capecitabine · Oncology
Oxaliplatin and capecitabine work together as a chemotherapy combination where oxaliplatin cross-links DNA to prevent replication while capecitabine is converted to fluorouracil to inhibit thymidylate synthase and disrupt nucleotide synthesis.
Phase 3 pipeline
- docetaxel plus oxaliplatin and capecitabine · Oncology
Docetaxel works by inhibiting microtubule dynamics, while oxaliplatin induces DNA damage and interstrand crosslinks, and capecitabine is a thymidylate synthase inhibitor.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: